New GLP-1 Study Raises Metabolic Health Questions @metabolicmind
New GLP-1 Study Raises Metabolic Health Questions  @metabolicmind
Uploaded August 2026 | Updated September 2026, 3 hours ago
Do GLP-1 medications improve metabolic health as much as they support weight loss? A new observational study in the Annals of Internal Medicine raises an important question about semaglutide, insulin discontinuation, type 2 diabetes, and what meaningful metabolic improvement may require.

In this episode of Metabolic Mind, Dr. Bret Scher breaks down a real-world study of more than 9,000 veterans with type 2 diabetes who were using insulin and then added either a GLP-1 receptor agonist, SGLT2 inhibitor, or DPP4 inhibitor. Despite semaglutide’s stronger association with weight loss, the study found similar insulin discontinuation rates across all three groups over three years.

Dr. Scher covers:

- Why weight loss and metabolic health improvements may not always move together
- What insulin discontinuation can reveal about insulin resistance and beta cell function
- Why semaglutide did not outperform older diabetes medications in this study
- The limitations of observational research and real-world medication data
- How GLP-1 medications and therapeutic carbohydrate reduction may work through complementary mechanisms
- Why combining GLP-1s with therapeutic carbohydrate reduction may be an important area for future research and clinical practice

This conversation takes a closer look at what metabolic health means, and why the path from weight loss to insulin independence may be more complex than the scale alone can show.

👉 Want to stay up to date with the latest research on metabolic health and metabolic psychiatry? Sign up for our newsletter to stay informed: metabolicmind.org/about-us/newsletter

🔎 Have questions about how to apply metabolic therapies effectively? Submit them at metabolicmind.org/questions to be featured in a future Metabolic Mailbag episode.

#MetabolicMind #KetogenicTherapy #GLP1

*Expert Featured:*
Bret Scher, MD - Baszucki Group Medical Director & Host of the Metabolic Mind Podcast
- linkedin.com/in/bret-scher-08baaa102
- instagram.com/drscher858/?hl=en
- https://x.com/bschermd

*Resources Mentioned:*
*Comparative Effectiveness of Glucagon-like Peptide-1 Receptor Agonists Versus Oral Agents for Insulin Discontinuation in Type 2 Diabetes : A Target Trial Emulation*
- acpjournals.org/doi/10.7326/ANNALS-25-05216

*Free CME Clinician Trainings:*
Are you a clinician who would like to learn more about the science behind these therapies and how to implement them in practice? Earn CME with our growing library of courses from some of the top experts in the field including Dr. Chris Palmer, Dr. Georgia Ede, Dr. Matthew Bernstein, Dr. Mariela Glandt, Dr. Deanna Kelly, Dr. Julie Milder, Dr. Zoltan Sarnyai, and Dr. Bret Scher with more coming soon.

Our courses have been made *FREE* by grants from Baszucki Group, so we can spread these powerful therapies as widely as possible. Earn CME/CNE credits:
metabolicmind.org/for-clinicians/trainings-courses/?utm_medium=organic-social&utm_source=youtube&utm_campaign=cme-yt

Follow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry.

Learn more about metabolic psychiatry and find helpful resources at metabolicmind.org

*About us:*
Metabolic Mind is a non-profit initiative of Baszucki Group working to transform the study and treatment of mental disorders by exploring the connection between metabolism and brain health. We leverage the science of metabolic psychiatry and personal stories to offer education, community, and hope to people struggling with mental health challenges and those who care for them.

Our channel is for informational purposes only. We are not providing individual or group medical or healthcare advice nor establishing a provider-patient relationship. Many of the interventions we discuss can have dramatic or potentially dangerous effects if done without proper supervision. Consult your healthcare provider before changing your lifestyle or medications.

*Timestamps:*
0:00 - Can GLP-1 Weight Loss Improve Metabolic Health? A New Semaglutide Study Explained
0:33 - Why Semaglutide Didn't Help More Patients Stop Insulin Than Older Diabetes Medications
2:50 - Weight Loss vs. Metabolic Health: Why They're Not Always the Same Thing
3:18 - GLP-1 Medications vs. Ketogenic Therapy: Different Ways to Improve Insulin Resistance
4:07 - Why Combining GLP-1 Medications with a Ketogenic Diet May Improve Metabolic Health
5:00 - The Biggest Takeaway: Weight Loss Alone Doesn't Equal Metabolic Recovery
New GLP-1 Study Raises Metabolic Health QuestionsKeto for Psychosis? New RCT Results Are InFell Out of Ketosis? Here’s How to Get Back FastQ&A: Keto for Women, Dairy, Net Carbs, PCOS & MoreSetting the Record Straight on NATURE-CT and Ketogenic DietsThe 3 Levers That Shape Your BrainTwo LDL Trials. Two Different Results.This Discovery Could Change Schizophrenia TreatmentDepression and Metabolism: What This New Study RevealsThe Shift That Could Change Mental HealthcareAnimal Protein vs Plant Protein: Top Health Authorities DisagreeHealing Depression Takes Consistency
Metabolic Mind |

New GLP-1 Study Raises Metabolic Health Questions

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER